ABION Presents Preclinical Data at AACR Showing IFN-β Antibody Fusion ABN202 Outperforms TROP2-Targeting ADCs
– Accelerating preclinical development toward IND submission in H1 next year, positioning ABN202 as a potential game changer in oncology SEOUL, South Korea–(BUSINESS WIRE)–#AACR2026—ABION (KOSDAQ, 203400), a precision oncology therapeutics developer, announced that its next-generation immuno-oncology candidate, ABN202, demonstrated a superior anti-cancer mechanism compared with TROP2-targeting antibody-drug conjugates (ADCs) in preclinical studies. The findings will … [Read more…]
